Nanomedicine : nanotechnology, biology, and medicine最新文献_第3页

Smart polymersome carriers for osteoporosis treatment: Enhanced bone regeneration via targeted teriparatide delivery 用于骨质疏松治疗的智能聚合体载体：通过靶向特立帕肽递送增强骨再生。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-18 DOI: 10.1016/j.nano.2025.102891

Safoora Poorirani , Mina Mirian , Farshid Hassanzadeh , Ali N. Kamali , Adel Mohammadalipour , Mohammad Hashemnia , Sayed Abolfazl Mostafavi

{"title":"Smart polymersome carriers for osteoporosis treatment: Enhanced bone regeneration via targeted teriparatide delivery","authors":"Safoora Poorirani , Mina Mirian , Farshid Hassanzadeh , Ali N. Kamali , Adel Mohammadalipour , Mohammad Hashemnia , Sayed Abolfazl Mostafavi","doi":"10.1016/j.nano.2025.102891","DOIUrl":"10.1016/j.nano.2025.102891","url":null,"abstract":"<div><div>Targeted drug delivery improves therapeutic efficacy while minimizing off-target effects. In this study, PLGA-PEG-Su-Asp (PPSA) copolymers were synthesized to develop teriparatide-loaded nano-polymersomes (PPSA-PTH1-34 NP) for bone-targeted delivery. Nanoparticles were prepared by nanoprecipitation and optimized using a central composite design. The optimized nanoparticles had a size of 245.78 ± 8.2 nm, PDI of 0.352 ± 0.12, ZP of −18.89 ± 0.1 mV, and 72.20 ± 2.9 % drug entrapment efficiency. PPSA-PTH 1–34 exhibited strong affinity (64.86 %) to hydroxyapatite, enhancing targeting efficiency. <em>In vitro</em> assays in MG-63 cells confirmed time- and concentration-dependent proliferation, uptake efficiency, increased ALP activity, and mineralization. <em>In vivo</em> studies using an (ovariectomizd) OVX rat model showed that PPSA-PTH 1–34 significantly improved bone regeneration compared to free PTH1–34. These findings demonstrate that PPSA-based NP provide a promising platform for targeted and sustained PTH 1–34 delivery, potentially improving therapeutic outcomes in osteoporosis treatment.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102891"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Black phosphorus-based drug nanocarrier for synergetic chemo-, chemo-dynamic, and photo-dynamic therapy of liver cancer 以黑磷为基础的药物纳米载体协同化疗、化疗动力和光动力治疗肝癌。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-07 DOI: 10.1016/j.nano.2025.102886

Jun Liu , Xiaoyu Hu , Qingrong Wang , Qiongkun Hu , Guanghao Yu , Yu Zhao , Liwei Gu , Jianying Shen , Qinghe Zhao , Feng Sui , Jingjing Zhu , Hai Ma

{"title":"Black phosphorus-based drug nanocarrier for synergetic chemo-, chemo-dynamic, and photo-dynamic therapy of liver cancer","authors":"Jun Liu , Xiaoyu Hu , Qingrong Wang , Qiongkun Hu , Guanghao Yu , Yu Zhao , Liwei Gu , Jianying Shen , Qinghe Zhao , Feng Sui , Jingjing Zhu , Hai Ma","doi":"10.1016/j.nano.2025.102886","DOIUrl":"10.1016/j.nano.2025.102886","url":null,"abstract":"<div><div>Limited therapeutic efficacy and significant toxicity consistently restrict the clinical development of chemotherapeutic drugs. To address these limitations, we engineered a multifunctional TAF-BP-DOX nanoplatform through the strategic combination of BP, doxorubicin, and a metal-polyphenol network (TAF). This rationally designed system exhibits dual responsiveness to tumor microenvironment characteristics, specifically acidic pH and elevated H<sub>2</sub>O<sub>2</sub> levels. Upon NIR irradiation, the platform orchestrates a synergistic combination of chemotherapy, chemodynamic therapy, and photodynamic therapy, demonstrating markedly enhanced anti-hepatoma activity in both cellular and animal models compared to monotherapy approaches using either free DOX or TAF-DOX. Importantly, comprehensive evaluations revealed that the TAF-BP-DOX system not only improves therapeutic outcomes but also substantially mitigates the cardiotoxicity typically associated with DOX treatment. These collective findings position TAF-BP-DOX as a highly promising nanotherapeutic platform.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102886"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic and biodistribution (PK/BD) study of ProGel-Dex, a thermoresponsive dexamethasone prodrug for sustained joint pain relief in a mouse model of osteoarthritis 热响应性地塞米松前药ProGel-Dex在骨关节炎小鼠模型中的药代动力学和生物分布（PK/BD）研究

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-04 DOI: 10.1016/j.nano.2025.102885

Xin Wei , Gang Zhao , Xiaoke Xu , Zhenshan Jia , Devendra Kumar , Evan Glissmeyer , Daniel Tran , Haochen Jiang , Sumbal Talib , Ningrong Chen , Zhulian Wang , Yazen Alnouti , Steven R. Goldring , Dong Wang

{"title":"Pharmacokinetic and biodistribution (PK/BD) study of ProGel-Dex, a thermoresponsive dexamethasone prodrug for sustained joint pain relief in a mouse model of osteoarthritis","authors":"Xin Wei , Gang Zhao , Xiaoke Xu , Zhenshan Jia , Devendra Kumar , Evan Glissmeyer , Daniel Tran , Haochen Jiang , Sumbal Talib , Ningrong Chen , Zhulian Wang , Yazen Alnouti , Steven R. Goldring , Dong Wang","doi":"10.1016/j.nano.2025.102885","DOIUrl":"10.1016/j.nano.2025.102885","url":null,"abstract":"<div><div>Intraarticular (IA) administration of ProGel-Dex was previously found to provide sustained joint pain relief with excellent safety in arthritis animal models. To explore ProGel-Dex’ working mechanisms, we conducted a comprehensive pharmacokinetics/biodistribution (PK/BD) study of IA ProGel-Dex and the free Dex released in an osteoarthritis mouse model. An initial “burst” release and distribution of ProGel-Dex was observed in all organs/tissues post IA administration. The higher-than-1.5 AUC<sub>inf_obs</sub>/AUC<sub>all</sub> ratios for both ProGel-Dex and free Dex support their long-term presence within the DMM joint beyond the experimental endpoint. The overall systemic organ/tissue exposures to ProGel-Dex and free Dex released were found to be much lower than those detected within the OA joint with IA ProGel-Dex. Together, these data support that the potent and long-sustained OA joint pain relief and the excellent safety of IA ProGel-Dex can be attributed to its prolonged retention in OA joint and the pathology-driven local activation.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102885"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting prostate cancer through reactive oxygen species: Advances in photothermal and sonodynamic therapies 通过活性氧靶向前列腺癌：光热和声动力疗法的进展。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-11-23 DOI: 10.1016/j.nano.2025.102881

Ridha.M. Lefta , Samer Saleem Alshkarchy , Thekra F. Ali , Majid S. Jabir , Wesam R. Kadhum

{"title":"Targeting prostate cancer through reactive oxygen species: Advances in photothermal and sonodynamic therapies","authors":"Ridha.M. Lefta , Samer Saleem Alshkarchy , Thekra F. Ali , Majid S. Jabir , Wesam R. Kadhum","doi":"10.1016/j.nano.2025.102881","DOIUrl":"10.1016/j.nano.2025.102881","url":null,"abstract":"<div><div>Prostate cancer (PCa) remains a major clinical challenge due to limited treatment efficacy, frequent resistance, and high recurrence rates. Given the susceptibility of cancer cells to oxidative stress, reactive oxygen species (ROS)-based strategies offer promising therapeutic potential. Photothermal therapy (PTT) and sonodynamic therapy (SDT) are emerging minimally invasive modalities that exploit nanotechnology to induce localized ROS generation. This review highlights recent advances in ROS-mediated PTT and SDT for PCa, emphasizing nanomaterial design and functionalization to enhance targeting precision, drug delivery, and overcome tumor hypoxia. Combining PTT and SDT with chemotherapy, radiotherapy, or immunotherapy produces synergistic effects, potentially overcoming resistance and eliciting systemic antitumor immunity. Preclinical studies demonstrate effective tumor eradication and immune activation with minimal toxicity, suggesting promise for clinical translation. However, human clinical trials remain scarce, and further translational research is needed before these nanotechnology-based approaches can be integrated into standard PCa treatment.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102881"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145605237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chinese herbal medicine-derived nanovesicles for combatting cancers 用于抗癌的中草药衍生纳米囊泡。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-11 DOI: 10.1016/j.nano.2025.102888

Bingjie Guan , Shunchao Zhang , Yuhan Wei , Jianing Jian , Chunguang Li , Zekun Wang , Haoran Qu , Zhigang Li , Mengya Liu , Juntao Wang

{"title":"Chinese herbal medicine-derived nanovesicles for combatting cancers","authors":"Bingjie Guan , Shunchao Zhang , Yuhan Wei , Jianing Jian , Chunguang Li , Zekun Wang , Haoran Qu , Zhigang Li , Mengya Liu , Juntao Wang","doi":"10.1016/j.nano.2025.102888","DOIUrl":"10.1016/j.nano.2025.102888","url":null,"abstract":"<div><div>The convergence of nanotechnology and extracellular vesicle (EV) research gives rise to Chinese herbal medicine-derived nanovesicles (CHMDNVs) that may serve as promising candidates in cancer therapy. Composed of lipids, proteins, nucleic acids, and diverse bioactive constituents, CHMDNVs can be isolated through various techniques; however, standardized protocols for their preparation remain to be established. CHMDNVs exhibit a favorable safety profile, with low toxicity, along with excellent stability and biocompatibility. Notably, their anticancer properties and tissue-specific targeting capabilities enable them to function both as intrinsic therapeutic agents, and as natural nanocarriers for targeted drug delivery. This review provides a comprehensive overview of results in this research field, including molecular composition, extraction and purification methods, therapeutic advantages, and preclinical applications of CHMDNVs in oncology. Furthermore, it outlines the limitations in current research, and suggests directions toward the clinical translation in the future.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102888"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of sources of variability in a nitric oxide screening assay for engineered nanomaterials 评估工程纳米材料的一氧化氮筛选试验的变异性来源。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-11-18 DOI: 10.1016/j.nano.2025.102878

Tariq Fahmi , Robert Gutierrez , Ana C. Barrios , Tae Joon Cho , John T. Elliott , Sanghamitra Majumdar , Bryant C. Nelson , Aaron C. Johnston-Peck , Alessandro Tona , Anil K. Patri , Elijah J. Petersen

{"title":"Evaluation of sources of variability in a nitric oxide screening assay for engineered nanomaterials","authors":"Tariq Fahmi , Robert Gutierrez , Ana C. Barrios , Tae Joon Cho , John T. Elliott , Sanghamitra Majumdar , Bryant C. Nelson , Aaron C. Johnston-Peck , Alessandro Tona , Anil K. Patri , Elijah J. Petersen","doi":"10.1016/j.nano.2025.102878","DOIUrl":"10.1016/j.nano.2025.102878","url":null,"abstract":"<div><div>Assays to detect potential biocompatibility issues can play a key role in supporting the development of new technologies such as medical products containing engineered nanomaterials (ENMs). A consensus test method standard on nitric oxide production after cellular ENM exposure was developed and published through ASTM International. In this paper, we describe an evaluation of sources of variability in this method. A significant challenge is ensuring that the protocol contains the necessary control measurements to account for potential issues when testing ENMs. Protocol testing was conducted during draft standard development and post-publication to better understand potential sources of variability such as the impact of insufficient removal of the ENM, the number of cells seeded, the selection of positive control compounds, and the culture techniques of the cells prior to the experiments. Several in-process control measurements were used to monitor the performance of intermediate steps in the assay procedure. Two gold nanoparticles with different surface coatings and nano-sized polystyrene particles were used to demonstrate the applicability of some of the control measurements. This testing revealed which sources of variability were more likely to have a significant impact on the overall assay uncertainty and confirmed the key importance of certain control measurements. These results could also support the standardization of other ENM-related <em>in vitro</em> methods that share similarities in their protocols with the method investigated here. The further development of this method can also support its use to evaluate the potential for substances other than ENMs to induce nitric oxide production.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102878"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “tailored iron oxide nanoparticles for biomedical applications: Hydroxyethyl starch coating enhances endothelial biocompatibility” [nanomedicine: Nanotechnology, biology and medicine, volume 71, January 2026, 102880] “用于生物医学应用的定制氧化铁纳米颗粒：羟乙基淀粉涂层增强内皮生物相容性”的勘误表[纳米医学：纳米技术，生物学和医学，第71卷，2026年1月，102880]。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-20 DOI: 10.1016/j.nano.2025.102893

Lydia-Nefeli Thrapsanioti , Andrey N. Kuskov , Aikaterini Berdiaki , Anna L. Luss , Elizaveta R. Vlaskina , Anna V. Ivanova , Maxim A. Abakumov , Maria Marmara , Kalliope Plexousaki , Aristides Tsatsakis , Dragana Nikitovic

引用次数: 0

Enhanced cellular and transdermal delivery of the modified chromatin using gH625 cell-penetrating peptide 使用gH625细胞穿透肽增强修饰染色质的细胞和透皮递送

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-11-28 DOI: 10.1016/j.nano.2025.102884

Xinghan Zhang, Yuxin Liang, Francesco Zonta, Jeong Hyeon Park

{"title":"Enhanced cellular and transdermal delivery of the modified chromatin using gH625 cell-penetrating peptide","authors":"Xinghan Zhang, Yuxin Liang, Francesco Zonta, Jeong Hyeon Park","doi":"10.1016/j.nano.2025.102884","DOIUrl":"10.1016/j.nano.2025.102884","url":null,"abstract":"<div><div>Development of a transdermal drug delivery system must overcome the limited efficacy and reliability of current skin penetration methods. This study examined whether synthetic chromatin conjugated with the cell-penetrating peptide gH625 could traverse the epidermal barrier while maintaining cargo bioactivity. gH625-linked histone H2A assembled into chromatin was used to deliver DNA and peptides without penetration enhancers. gH625–chromatin increased cellular penetration by 150% compared with wild-type chromatin. Ex vivo porcine and in vivo mouse skin models demonstrated enhanced penetration depth up to 242 μm within 24 h, with signals confined to the dermis, indicating safe localized delivery. Epidermal growth factor (EGF) displayed at the histone H2B C-terminus maintained activity equivalent to free EGF, promoting cell growth, elevated COL1A1 secretion, and accelerated wound closure. These findings establish a chromatin-based nanoplatform for non-invasive transdermal delivery of bioactive macromolecules, filling a key gap in skin-targeted biotherapeutic delivery.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102884"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145621415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics 靶向药物递送的智能生物偶联mof：白蛋白和球蛋白对mebeverine释放动力学的影响

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-11-24 DOI: 10.1016/j.nano.2025.102882

Esra Maltas Cagil , Lola Yakhshilikova , Mustafa Ersoz

{"title":"Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics","authors":"Esra Maltas Cagil , Lola Yakhshilikova , Mustafa Ersoz","doi":"10.1016/j.nano.2025.102882","DOIUrl":"10.1016/j.nano.2025.102882","url":null,"abstract":"<div><div>Mebeverine (MBV) is a clinically approved antispasmodic agent indicated for irritable bowel syndrome (IBS) that functions via direct calcium channel inhibition in gastrointestinal smooth muscle, alleviating spasmodic pain without central anticholinergic effects. Optimal oral delivery mandates protection from gastric acidity (pH ~1.5–3.0) and targeted release in the small intestine (pH ~6.0–7.4) for prompt onset and sustained action. Here, we report a comparative evaluation of tartaric acid–iron(III) metal–organic frameworks (TF-MOFs) functionalized with globulin (TF-GLB) or human serum albumin (TF-HSA), loaded with MBV. TF-GLB-MBV released a higher amount of MBV at 7.4 and 9.0, suggesting unsuitability for neutral and basic environments with a concentration of 2.06 mg (12.73 %) and 3.67 mg (22.69 %) at first 15 min, respectively. For TF-HSA-MBV, the maximum MBV release amounts were 3.58 mg (5.22 %) and 0.9 mg (21.20 %), respectively. This comparative kinetic modeling study reveals that TF-HSA-MBV performs optimally in acidic and alkaline environments, following Higuchi diffusion-based release. Meanwhile, TF-GLB-MBV is more suitable for mildly acidic pH, exhibiting Case II transport, suggesting erosion- or swelling-controlled release—ideal for upper intestinal targeting. However, neither formulation performed optimally at physiological pH (7.4), which may require further formulation optimization. These findings support TF-GLB as a promising oral delivery system for IBS.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102882"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145621414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-Organ-on-Chip approach to exploring breast cancer liver metastases concerning the endothelial barrier and the influence of immune cells 多器官芯片技术探讨乳腺癌肝转移的内皮屏障和免疫细胞的影响。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-08 DOI: 10.1016/j.nano.2025.102890

Joanna Konopka , Joanna Roszczyk , Elżbieta Jastrzębska , Agnieszka Żuchowska

{"title":"Multi-Organ-on-Chip approach to exploring breast cancer liver metastases concerning the endothelial barrier and the influence of immune cells","authors":"Joanna Konopka , Joanna Roszczyk , Elżbieta Jastrzębska , Agnieszka Żuchowska","doi":"10.1016/j.nano.2025.102890","DOIUrl":"10.1016/j.nano.2025.102890","url":null,"abstract":"<div><div>Cancer metastasis is the spread of cancerous cells through the circulatory system to distant organs. Existing <em>in vitro</em> models remain insufficient to faithfully reproduce the metastatic process. Multi-Organ-on-Chip (multi-OoC) platforms allow the integration of complex tissue models. Here, we propose a microplatform that recapitulates breast cancer (BC) migration to the liver, considering an endothelial barrier (EB) and immune cell interactions. Tissue micromodels were created using agarose multi-wells, loaded into the microplatform, and separated by different types of barriers: (i) collagen type I, (ii) cell culture medium, (iii) immune (Jurkat) cells, (iv) a microvessel, and (v) a microvessel perfused with Jurkat cells. Spatial arrangement of cells, their morphology, and viability were imaged using fluorescence microscopy over 10-day experiments. Quantitative data such as Feret Diameter, relative Raw Integrated Density (ID) and migration distance of tumor cells (GFP-MDA-MB-231) were evaluated. The concentrations of metastatic agents (interleukin-6 (IL-6), and interleukin-11 (IL-11)) were determined using ELISA. The potential of a microplatform in drug screening was preliminarily assessed with the use of Doxorubicin (Dox) over a 7-day experiment. Changes in Feret diameter and ID indicated a gradual disintegration of the BC micromodel. BC cells migrated toward the liver micromodel through a barrier formed in the central microchannel. An EB was impenetrable for GFP-MDA-MB-231, whereas Jurkat cells promoted the migration of BC cells. Dox induced transient inflammation and suppressed IL-11-dependent pro-metastatic signaling, consistent with its dual cytotoxic and immunomodulatory roles.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102890"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0